Adjuvant therapy with levamisole in resectable lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Surgical Oncology

Background:

• Cytotoxic chemotherapy has shown limited success as an adjuvant treatment for resectable lung cancer.
• There is a need for effective adjuvant therapies to improve outcomes for lung cancer patients post-surgery.

Purpose of the Study:

• To evaluate the efficacy and safety of adjuvant levamisole in resectable lung cancer patients.
• To determine if levamisole dosage impacts treatment outcomes in this patient population.

Main Methods:

• A double-blind, placebo-controlled trial involving 211 resectable lung cancer patients.
• Patients received either levamisole or placebo for 2 years post-operation, with varying dosages.
• Patient outcomes, including recurrence and death, were monitored for 2 years.

Main Results:

• High-dose levamisole (2.1–3.8 mg/kg) significantly reduced cancer recurrence and deaths compared to placebo.
• Patients with more advanced cancers appeared to benefit more from levamisole treatment.
• Levamisole showed a potential advantage in preventing hematogenous spread over local recurrences.

Conclusions:

• Adequately dosed levamisole is a potentially effective and safe adjuvant treatment for resectable lung cancer.
• Levamisole's efficacy did not depend on tumor histology or baseline immune status.
• Further research into optimal dosing and specific mechanisms of action is warranted.